Priya Kishnani, MD, a Professor of Pediatrics at the Duke University School of Medicine, discusses recent results from the COMET study, which is a noninferiority study designed to assess the efficacy of avalglucosidase alfa, a new enzyme replacement therapy, compared with alglucosidase alfa, the current enzyme replacement therapy, for the treatment of late-onset Pompe disease. Treatment with avalglucosidase alfa demonstrated greater improvements in upright FVC % predicted and a 2.43% greater increase in upright FVC % predicted at 49 weeks compared with alglucosidase alfa.